Catalent Pharma Solutions Inc. negotiated a decrease in the interest rates of its U.S. dollar-denominated and euro-denominated term loans.

The Catalent Inc. subsidiary will pay 2.75% plus LIBOR on its U.S. dollar-denominated loan, down 0.50% on the previous rate, and 2.50% plus LIBOR on euro-denominated loan, 0.75% lower than the prior rate.

Catalent Inc. had $1.45 billion outstanding under its U.S. dollar-denominated term loan facility as of Sept. 30; it had $350.5 million outstanding under its euro-denominated facility on the same date.